The prognostic value of 18F-FDG PET/CT in patients with extranodal natural killer/T-cell lymphoma
-
摘要: 结外NK/T细胞淋巴瘤（extranodal natural killer/T-cell lymphoma，ENKTL）是一种与EB病毒（epstein-barr virus，EBV）相关的侵袭性非霍奇金淋巴瘤（non-Hodgkin's lymphoma，NHL），好发于亚洲和南美洲，其病程进展较快、病死率较高、预后不佳。目前应用的预后模型主要包括国际预后指数（international prognostic index，IPI）、韩国预后指数（Korean prognostic index，KPI）、NK细胞淋巴瘤预后指数（prognostic index of natural killer cell lymphoma，PINK）及包含EBV DNA的NK细胞淋巴瘤预后指数（prognostic index of natural killer cell lymphoma with epstein-barr virus DNA，PINK-E），尚存在一定的局限性。正电子发射断层显像融合计算机断层扫描（positron emission tomography/computed tomography，PET/CT）是一种将解剖结构成像和代谢功能成像相结合的影像技术，具有高敏感性、高特异性的优势，在多种恶性淋巴瘤的诊断、分期、疗效评价和预后评估等方面发挥重要的作用，但其对于ENKTL的预后价值仍存争议。因此，本文针对治疗前、治疗中期和治疗结束后PET/CT对于ENKTL的预后价值进行综述。
-
关键词:
- 结外NK/T细胞淋巴瘤 /
- 预后模型 /
- 18F-FDG /
- PET/CT /
- 预后价值
Abstract: Extranodal natural killer/T-cell lymphoma (ENKTL) is an Epstein-Barr virus-associated aggressive non-Hodgkin's lymphoma (NHL). It is prevalent in Asia and South America with an aggressive clinical course and a dismal prognosis. Currently, the prognostic models that are commonly used for ENKTL include the International Prognostic Index (IPI), Korean Prognostic Index (KPI), Prognostic Index of Natural Killer Cell Lymphoma (PINK), and Prognostic Index of Natural Killer Cell Lymphoma with Epstein-Barr virus DNA (PINK-E), all of which have some limitations. Positron emission tomography/computed tomography (PET/CT) is a new imaging technique combining anatomical and functional imaging, with the advantages of high sensitivity and specificity, which is essential for diagnosis, staging, efficacy evaluation, and prognosis prediction of various malignant lymphomas. However, the prognostic value of PET/CT in ENKTL remains controversial. Therefore, in this article, we review relevant studies on the prognostic value of pretreatment, interim, and end-oftreatment PET/CT in patients with ENKTL.-
Key words:
- extranodal natural killer/T-cell lymphoma /
- prognostic model /
- 18F-FDG /
- PET/CT /
- prognostic value
-
表 1 18F-FDG PET/CT在结外NK/T细胞淋巴瘤预后价值的相关研究
-
[1] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375. doi: 10.1182/blood-2016-01-643569 [2] Tse E, Kwong YL. How I treat NK/T-cell lymphomas[J]. Blood, 2013, 121(25):4997-5005. doi: 10.1182/blood-2013-01-453233 [3] Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China analysis of 4 638 cases according to the world health organization classification[J]. Am J Clin Pathol, 2012, 138(3):429-434. doi: 10.1309/AJCP7YLTQPUSDQ5C [4] Au Wy, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-Cell lymphoma project[J]. Blood, 2009, 113(17):3931-3937. doi: 10.1182/blood-2008-10-185256 [5] Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25):4124-4130. doi: 10.1200/JCO.2008.16.4558 [6] The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive Non-Hodgkin's lymphoma[J]. N Engl J Med, 1993, 329(14):987-994. doi: 10.1056/NEJM199309303291402 [7] Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. doi: 10.1200/JCO.2005.04.1384 [8] Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1 [9] Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma[J]. J Clin Oncol, 2007, 25(5):571-578. doi: 10.1200/JCO.2006.08.2305 [10] Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854. doi: 10.1200/JCO.2010.32.5225 [11] Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma[J]. J Nucl Med, 2009, 5(50 Suppl 1):S21-S30. [12] Khong PL, Pang CBY, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies[J]. Ann Hematol, 2008, 87(8):613-621. doi: 10.1007/s00277-008-0494-8 [13] Chan WKS, Au WY, Wong CYO, et al. Metabolic activity measured by 18F-FDG PET in natural killer-cell lymphoma compared to aggressive B-and T-cell lymphomas[J]. Clin Nucl Med, 2010, 35(8):571-575. doi: 10.1097/RLU.0b013e3181e4dcbf [14] Moon SH, Cho SK, Kim WS, et al. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods[J]. J Nucl Med, 2013, 54(7): 1039-1044. doi: 10.2967/jnumed.112.113399 [15] Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma[J]. Eur J Haematol, 2011, 87(2):123-129. doi: 10.1111/ejh.2011.87.issue-2 [16] Bai B, Huang HQ, Cai QC, et al. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma[J]. Med Oncol, 2013, 30(1):339. doi: 10.1007/s12032-012-0339-0 [17] Jiang C, Zhang X, Jiang M, et al. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Nucl Med, 2015, 29(5):442-451. doi: 10.1007/s12149-015-0964-8 [18] Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on 18F-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis[J]. Am J Otolaryngol, 2018, 39(1):1-5. doi: 10.1016/j.amjoto.2017.10.009 [19] Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma [J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1321-1329. doi: 10.1007/s00259-013-2443-6 [20] Chang Y, Fu X, Sun Z, et al. Utility of baseline, interim and end-oftreatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J]. J Hematol Oncol, 2017, (7):41057. https://www.researchgate.net/publication/270342830_Evaluation_of_bone_marrow_involvement_in_extranodal_NKT_cell_lymphoma_by_FDG-PETCT [21] Jiang C, Su M, Kosik RO, et al. The deauville 5-point scale improves the prognostic value of interim FDG PET/CT in extranodal natural killer/T-cell lymphoma[J]. Clin Nucl Med, 2015, 40(10):767-773. doi: 10.1097/RLU.0000000000000892 [22] Khong PL, Huang B, Phin Lee EY, et al. Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center[J]. J Nucl Med, 2014, 55(6):911-916. doi: 10.2967/jnumed.113.131946 [23] Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET scan in lymphoma[J]. Leuk Lymphoma, 2009, 50(8):1257-1260. doi: 10.1080/10428190903040048 [24] Jiang C, Liu J, Li L, et al. Predictive approaches for post-therapy PET/ CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study[J]. Nucl Med Commun, 2017, 38(11):937. doi: 10.1097/MNM.0000000000000731 [25] Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type[J]. Clin Cancer Res: An Offi J Am Associ Cancer Res, 2012, 18(15):4183-4190. doi: 10.1158/1078-0432.CCR-12-1064 [26] Kwong YL, Pang AWK, Leung AYH, et al. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance[J]. Leukemia, 2014, 28(4):865-870. doi: 10.1038/leu.2013.212 [27] Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2011, 118(23):6018-6022. doi: 10.1182/blood-2011-05-354142 [28] Kim SJ, Choi JY, Hyun SH, et al. Risk stratification on the basis of deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis[J]. Lancet Haematol, 2015, 2(2):e66-e74. doi: 10.1016/S2352-3026(15)00002-2 [29] Lim SH, Hyun SH, Kim HS, et al. Prognostic relevance of pretransplant deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL[J]. Bone Marrow Transplant, 2016, 51(6):807-812. doi: 10.1038/bmt.2016.6 [30] Song MK, Chung JS, Shin HJ, et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma[J]. Leuk Res, 2013, 37(1):58-63. doi: 10.1016/j.leukres.2012.09.011 [31] Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck[J]. J Nucl Med, 2008, 49(11):1783-1789. doi: 10.2967/jnumed.108.053355 [32] 丁重阳, 吴宇霖, 杨文平, 等.治疗前18F-FDG PET-CT最大标准摄取值在结外NK/T细胞淋巴瘤中的预后意义[J].影像诊断与介入放射学, 2015, 24(3):242-246. [33] 黄琴, 刘虹, 杨晓丰, 等.化疗中期18F-FDG PET/CT显像对自然杀伤/T细胞淋巴瘤的预后评价[J].中华核医学与分子影像杂志, 2017, (10):618-622. doi: 10.3760/cma.j.issn.2095-2848.2017.10.004 -
点击查看大图
表(1)
计量
- 文章访问数: 51
- HTML全文浏览量: 19
- PDF下载量: 2
- 被引次数: 0
下载:
